Related Experiment Video
Updated: Nov 12, 2025
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
How Do We Meet the Challenge of Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors?
Adam J Schoenfeld1, Roisin E O'Cearbhaill
1From the Cellular Therapy Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Department of Medicine, Weill Cornell Medical College, New York, NY.
Abstract:
Immune checkpoint inhibition has vastly improved the treatment of solid tumors, but most patients do not experience durable clinical benefit, so novel immunotherapeutic approaches are needed. Autologous T cells genetically engineered to express chimeric antigen receptors (CARs) have led to unprecedented clinical success in hematologic malignancies, and increasing efforts are actively being pursued to translate these benefits to the solid tumor arena. However, solid tumors present unique challenges for CAR T-cell development. In this review, we examine the potential barriers to progress and present emerging approaches to overcome these challenges with CAR therapy in solid tumors.
Insights
Novel immunotherapies are crucial as most patients with solid tumors do not benefit from current immune checkpoint inhibitors. This review explores challenges and emerging strategies for chimeric antigen receptor (CAR) T-cell therapy in solid tumors.
Area of Science:
- Oncology
- Immunotherapy
- Cellular Therapy
Background:
- Immune checkpoint inhibition has improved solid tumor treatment, but durable responses are limited.
- Chimeric antigen receptor (CAR) T-cell therapy shows success in blood cancers, prompting exploration for solid tumors.
- Solid tumors present unique hurdles for effective CAR T-cell therapy development.
Purpose of the Study:
- To review the challenges hindering CAR T-cell therapy in solid tumors.
- To discuss emerging strategies for overcoming these obstacles.
- To highlight the potential of CAR T-cell therapy for solid tumor treatment.
Main Methods:
- Literature review of current research on CAR T-cell therapy in solid tumors.
- Analysis of barriers to CAR T-cell efficacy in the tumor microenvironment.
- Examination of novel CAR T-cell engineering and delivery approaches.
Main Results:
- Solid tumors present significant challenges including antigen heterogeneity, T-cell trafficking, and immunosuppressive microenvironments.
- Emerging strategies involve optimizing CAR T-cell design, enhancing tumor infiltration, and overcoming immune suppression.
- Preclinical and early clinical data suggest potential, but further research is needed.
Conclusions:
- Overcoming the unique challenges of the solid tumor microenvironment is key to successful CAR T-cell therapy.
- Innovative approaches are being developed to enhance CAR T-cell persistence and anti-tumor activity.
- CAR T-cell therapy holds promise for revolutionizing solid tumor treatment if current barriers are addressed.
